Bayer(US:BAYRY) Xin Hua She·2025-11-21 10:41Core Insights - Bayer has officially launched its Open Innovation Center in the International Pharmaceutical Innovation Park in Beijing, marking a significant step in fostering local pharmaceutical innovation and collaboration with high-level research institutions [1][2] - The park aims to incubate local innovative pharmaceutical companies and facilitate their global expansion, aligning with China's strategic focus on developing innovative drugs and medical devices [1][3] Group 1: Development and Infrastructure - The International Pharmaceutical Innovation Park covers an area of 5.8 square kilometers and is divided into four functional zones: headquarters cluster, medical-engineering integration area, R&D transformation area, and pharmaceutical manufacturing area [2][3] - The park has a built-up area of 280,000 square meters, with ongoing construction of supporting facilities for pharmaceutical R&D [2] Group 2: Industry Collaboration and Growth - The park is attracting major international pharmaceutical companies, including AstraZeneca and Medtronic, with 12 global pharmaceutical giants expected to establish operations [2][3] - The park is leveraging Beijing's policy, innovation, and openness advantages to create a preliminary agglomeration of the biopharmaceutical industry, with plans for more leading innovative drug and device companies to settle by 2026 [3] Group 3: Future Directions and Innovations - The park is set to develop an AI healthcare industry cluster, focusing on AI applications in pharmaceutical manufacturing and precision diagnosis [3] - A comprehensive ecosystem is being constructed, integrating industry chains, innovation chains, talent chains, and ecological chains to support the entire lifecycle of product development from R&D to large-scale production [3]